French startup Synapse Medicine has raised €25 million in a new round of funding. The funding round was led by Korelya Capital, Mutuelles Impact, and previous investors XAnge, MACSF, and BNP Paribas Développement.
Synapse Medicine, founded in 2017 by Clément Goehrs (CEO), Louis Létinier (Medical Director), and Bruno Thiao-Layel (Research Engineer), specializes in the proper use of medication by developing a SaaS platform for healthcare professionals that provides a comprehensive view of medication information.
2CFinance conducted financial due diligence of Synapse Medicine. Based in Bordeaux, the startup plans to use the funds to accelerate the deployment of its platform and triple its workforce to 150 people, with recruitment planned in Paris, Berlin, London, New York, and Tokyo.
The startup provides a software platform that uses artificial intelligence to help healthcare professionals prescribe medication more efficiently and safely. The software analyzes patient data and medical history to recommend the best medication for each individual patient, taking into account factors such as allergies or potential drug interactions. The platform also provides real-time alerts about any potential adverse reactions or complications.
The investment in Synapse Medicine highlights the growing importance of digital health startups, particularly in the wake of the COVID-19 pandemic. The startup has been recognized for its innovative approach to medication management, and the new funding will allow it to expand its reach and impact in the healthcare sector.
